Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. BioNTech SE is conducting a ...

This study could significantly impact BioNTech’s stock performance and investor sentiment, as successful results may enhance the company’s position in the oncology market. The involvement of ...

Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

Investors in BioNTech SE (Symbol: BNTX) saw new options begin trading today, for the June 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is ...

Investors in BioNTech SE (Symbol: BNTX) saw new options begin trading this week, for the April 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BNTX ...

BNTX's stock price jumped from $113 on 7 April 2021 to $447 on 9 August 2021. Since then, the stock’s price dropped 63%, even as the company reported strong 3Q 2021 and 4Q 2021 financial results.

BioNTech (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about ...